Derma Sciences (DSCI) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Derma Sciences Reports 2016 Second Quarter Financial Results
August 9, 2016 7:30 AM EDT
Operating loss narrowed to $2.0 million from $5.6 million a year ago
Advanced
Wound Care sales up 6.6%
2016 financial guidance revised to include recent transactions
Conference call begins at 11:00 a.m. Eastern Time today
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and six months ended June 30, 2016.
Business highlights of the second quarter of 2016 and recent weeks include:
... More